0Y3M Stock Overview
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Prothena Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.62 |
| 52 Week High | US$41.37 |
| 52 Week Low | US$13.24 |
| Beta | 0.16 |
| 11 Month Change | -2.16% |
| 3 Month Change | -25.28% |
| 1 Year Change | -55.20% |
| 33 Year Change | -69.22% |
| 5 Year Change | n/a |
| Change since IPO | -64.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y3M | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 11.7% | 1.5% | 2.2% |
| 1Y | -55.2% | -17.9% | 8.8% |
Return vs Industry: 0Y3M underperformed the UK Biotechs industry which returned -17.9% over the past year.
Return vs Market: 0Y3M underperformed the UK Market which returned 8.8% over the past year.
Price Volatility
| 0Y3M volatility | |
|---|---|
| 0Y3M Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0Y3M's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0Y3M's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 173 | Gene Kinney | www.prothena.com |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.
Prothena Corporation plc Fundamentals Summary
| 0Y3M fundamental statistics | |
|---|---|
| Market cap | US$811.44m |
| Earnings (TTM) | -US$131.83m |
| Revenue (TTM) | US$133.35m |
6.1x
P/S Ratio-6.2x
P/E RatioIs 0Y3M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y3M income statement (TTM) | |
|---|---|
| Revenue | US$133.35m |
| Cost of Revenue | US$234.24m |
| Gross Profit | -US$100.89m |
| Other Expenses | US$30.94m |
| Earnings | -US$131.83m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.45 |
| Gross Margin | -75.66% |
| Net Profit Margin | -98.86% |
| Debt/Equity Ratio | 0% |
How did 0Y3M perform over the long term?
See historical performance and comparison